ArQule
ArQule is Biopharmaceutical company with headquarters is in Massachusetts, USA.
Merck acquired ArQule in 2020 for 2.7 Billion USD.
World Top 100 HealthCare Products Companies List by Market Cap in January 2024, World Biggest 100 HealthCare Products Companies by Market Cap, World Largest 100 HealthCare Products Companies in the World by market cap as pf Jan-05-2024.
ArQule is Biopharmaceutical company with headquarters is in Massachusetts, USA.
Merck acquired ArQule in 2020 for 2.7 Billion USD.
Denali Therapeutics is a Biotechnology company focused on Neurodegenerative Diseases. The headquarters is in USA.
Patterson Companies has expertise in animal healthcare and human dentalcare solutions. It is also holding various leadership positions in sales, marketing, operations, national accounts and business development. The headquarters is in USA.
Patterson Companies Annual Total Revenue for year ending Apr-2023 was 6,471 million USD and and Net Income for year ending Apr-2023 was 207 million USD.
Patterson Companies Annual Total Revenue for year ending Apr-2023 was 6,499 million USD and and Net Income for year ending Apr-2023 was 203 million USD.
As on 2022, Patterson Companies has 6,500 employees.
As of April-2021, they had approximately 7,800 full-time employees
LivaNova is a Medical Technology company. The company products and therapies are neuromodulation, resources and cardiovascular. It offers a diverse product portfolio with a differentiated pipeline and reach is broad with a presence in more than 100 countries and approximately 4,000 employees. The headquarters is in UK.
Myovant Sciences is a biopharmaceutical company. It works for women and for men through purpose driven science, Empowering Medicines and Transformative Advocacy company. It have three clinical programs for relugolix which consisted of five international phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis associated pain and one in men with advanced prostate cancer. The headquarters is in UK.
Sumitovant Biopharma acquired Myovant Sciences for 1.7 billion USD in 2023.